Finance

Lists
Q3 2026 earnings • 3:00 PM tomorrow
See details
ABTT34:BVMF
Abbott Laboratories BDR
R$43.04
-1.37%
(-0.60) 1D
Oct 20, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for ABTT34...
Open
R$44.07
High
R$44.07
Low
R$42.64
Mkt. cap
177.28B
Avg. vol.
362.00
Volume
647.00
52-wk high
R$57.89
52-wk low
R$33.20
Shares outstanding
1.73B
No. of employees
115K
Open
R$44.07
High
R$44.07
Low
R$42.64
Mkt. cap
177.28B
Avg. vol.
362.00
Volume
647.00
52-wk high
R$57.89
52-wk low
R$33.20
Shares outstanding
1.73B
No. of employees
115K
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories BDR
CEORobert B. Ford
Employees115K
Founded1888
HeadquartersChicago, Illinois, United States
SectorMedical device
Websiteabbott.com
Next call in 16:37:11
Tomorrow, 3:00 PM
Fiscal period
Q3 2026
- / $1.41
Revenue / Est. (USD)
- / 12.99B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.37B
11.46B
11.16B
12.59B
Cost of goods sold
5.08B
4.91B
4.89B
5.32B
Cost of revenue
5.08B
4.91B
4.89B
5.32B
Research and development expenses
766.00M
720.00M
767.00M
892.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.90B
2.93B
3.58B
3.87B
Operating expense
4.09B
4.07B
4.77B
5.42B
Total operating expenses
9.16B
8.98B
9.66B
10.74B
Operating income
2.20B
2.48B
1.50B
1.85B
Other non operating income
2.00M
-15.00M
-
-25.00M
EBT including unusual items
2.18B
2.36B
1.45B
1.52B
EBT excluding unusual items
2.18B
2.44B
1.45B
1.52B
Income tax expense
536.00M
582.00M
372.00M
596.00M
Effective tax rate
24.59%
24.68%
25.67%
39.11%
Other operating expenses
-
-
-
-
Net income
1.64B
1.78B
1.08B
928.00M
Net profit margin
14.46%
15.50%
9.65%
7.37%
Earnings per share
1.30
1.50
1.15
1.31
Interest and investment income
77.00M
78.00M
106.00M
52.00M
Interest expense
-121.00M
-120.00M
-174.00M
-351.00M
Net interest expenses
-44.00M
-42.00M
-68.00M
-299.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.00B
3.27B
2.31B
2.91B
Gain or loss from assets sale
-
65.00M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps